Metsera Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Metsera Inc (MTSR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Peer Data As of Q3 2025
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/MTSR/competitors
https://api.csimarket.com/api/v1/companies/MTSR/relationships
https://api.csimarket.com/api/v1/companies/MTSR/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Metsera Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Metsera Inc | - | - | - | Yes |
| High-Confidence Competitors (138) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MTSR Stock Performance relative to its Competitors
MTSR
Competitors (weighted)
Percent change over the selected range
MTSR Stock Performance relative to High-Confidence Competitors
MTSR
High-Confidence Competitors (equal-weighted, 144)
Percent change over the selected range
Metsera Inc's Comment on Competition and Industry Peers
The company operates in the biotechnology sector, developing injectable and oral nutrient-stimulated hormone analog peptides targeting obesity and related conditions. It faces challenges including intellectual property protection, compliance with license agreements, and dependence on third parties for clinical trials and manufacturing. The company holds license agreements with D&D and Triple G, which involve royalty and sublicense income obligations. Amneal serves as a primary manufacturing partner, supplying drug substances and products, with contractual restrictions preventing Amneal from developing or supplying competing GLP-1 and amylin agonist products for competitors except under limited circumstances. Additionally, Amneal is constructing new manufacturing facilities in India dedicated to the company's injectable peptide drug products. Competitors identified in company filings include Amneal, D&D, and Triple G.
Competitor data is not yet available for Metsera Inc.
Metsera Inc's Competitors Named by the Company
Competitive relationships identified from Metsera Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicycle Therapeutics Plc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Nexgel Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Artelo Biosciences Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Sanofi | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Takeda Pharmaceuticals | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Nanoviricides inc | Company report | 85% |
| Neonc Technologies Holdings Inc | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Valneva Se | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Biontech Se | Company report | 85% |
| Novavax inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Verastem Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Cingulate Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Cardiff Oncology Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Triple G | Company report | 85% |
| INVO | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Ladrx Corporation | Company report | 85% |
| 22nd Century Group inc | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Heron Therapeutics Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| ENTO | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Curevac N v | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Maravai Lifesciences Holdings Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Bioatla Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| Kyowa Kirin | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Crinetics Pharmaceuticals Inc | Company report | 85% |
| Larimar Therapeutics Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Acrotech Biopharma | Company report | 85% |
| SHOT | Company report | 85% |
| Bonk Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| BMS | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Avenir Wellness Solutions Inc | Company report | 85% |
| Celgene | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Therapeuticsmd Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Beyondspring Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Janssen Biotech | Company report | 85% |
| RENB | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Dermata Therapeutics Inc | Company report | 85% |
| Protara Therapeutics Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Cocrystal Pharma Inc | Company report | 85% |
| Evofem Biosciences Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Tonix Pharmaceuticals Holding Corp | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Zyversa Therapeutics Inc | Company report | 85% |
| Biostax Corp | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Curis Inc | Company report | 85% |
| Geovax Labs Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Relmada Therapeutics Inc | Company report | 85% |
| Vbi Vaccines Inc | Company report | 85% |
| Amphastar Pharmaceuticals Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Matinas Biopharma Holdings Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Imunon Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Range Impact Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Organon and Co | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Sarepta Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Dr Reddy s Laboratories Limited | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Revolution Medicines Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Lianbio | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Arcturus Therapeutics Holdings Inc | Company report | 85% |
| Ionis Pharmaceuticals Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Roivant Sciences Ltd | Company report | 85% |
Competitor Evidence Detail
Company report basis, confidence, active dates and source counts for Metsera Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.